SCHEMBL454163

SCHEMBL454163

CCCCCCCC/C=C\CCCCCCCC(=O)Oc1ccccc1C(=O)O

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.75
RECQL P46063 2/20 0.75
MEN1 O00255 1/20 0.75
KMT2A Q03164 1/20 0.75
POLM Q9NP87 2/20 0.60
POLK Q9UBT6 2/20 0.60
POLL Q9UGP5 2/20 0.60
POLH Q9Y253 2/20 0.60
SOAT2 O75908 1/20 0.52
SOAT1 P35610 1/20 0.52
FAAH O00519 3/20 0.50
EPHX2 P34913 2/20 0.50
HTR2A P28223 1/20 0.50
ELANE P08246 1/20 0.49
CES1 P23141 1/20 0.48
CNR1 P21554 1/20 0.48
CNR2 P34972 1/20 0.48
ALDH1A1 P00352 4/20 0.48
F7 P08709 3/20 0.48
F3 P13726 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7710665 1.00 KDM4E (0.75) KDM4ERECQLMEN1KMT2APOLM
SCHEMBL17369039 1.00 KDM4E (0.75) KDM4ERECQLMEN1KMT2APOLM
SCHEMBL17369041 0.97 KDM4E (0.71) KDM4ERECQLMEN1KMT2APOLM
SCHEMBL16800411 0.97 KDM4E (0.71) KDM4ERECQLMEN1KMT2APOLM
SCHEMBL469664 0.96 KDM4E (0.73) KDM4ERECQLMEN1KMT2APOLM
SCHEMBL8439129 0.96 KDM4E (0.73) KDM4ERECQLMEN1KMT2APOLM
SCHEMBL17369042 0.95 KDM4E (0.71) KDM4ERECQLMEN1KMT2APOLM
SCHEMBL16770314 0.95 KDM4E (0.71) KDM4ERECQLMEN1KMT2APOLM
SCHEMBL16800484 0.95 KDM4E (0.71) KDM4ERECQLMEN1KMT2APOLM
SCHEMBL8814970 0.94 KDM4E (0.73) KDM4ERECQLMEN1KMT2APOLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2613779-A2 CONJUGATES OF POLYUNSATURATED FATTY ACIDS AND AMINE-CONTAINING COMPOUNDS AND USES THEREOF Medwell Laboratories Ltd. (IL) 2013-07-17 EP claimed
US-20130158070-A1 CONJUGATES OF POLYUNSATURATED FATTY ACIDS AND AMINE-CONTAINING COMPOUNDS AND USES THEREOF MEDWELL LABORATORIES LTD. (IL) 2013-06-20 US claimed
WO-2012032509-A2 CONJUGATES OF POLYUNSATURATED FATTY ACIDS AND AMINE-CONTAINING COMPOUNDS AND USES THEREOF MEDWELL LABORATORIES LTD. (IL) 2012-03-15 WO claimed
EP-4271356-A1 COMPOSITION FOR KERATIN FIBERS L'OREAL (FR) 2023-11-08 EP disclosed
WO-2022118978-A1 COMPOSITION FOR KERATIN FIBERS L'OREAL (FR) 2022-06-09 WO disclosed
WO-2022118982-A1 PROCESS FOR TREATING KERATIN FIBERS L'OREAL (FR) 2022-06-09 WO disclosed
WO-2022118980-A1 COMPOSITION FOR KERATIN FIBERS L'OREAL (FR) 2022-06-09 WO disclosed
EP-3086863-A1 COSMETIC COMPOSITIONS AND METHODS PROVIDING ENHANCED PENETRATION OF SKIN CARE ACTIVES The Procter & Gamble Company (US) 2016-11-02 EP disclosed
US-20160120995-A1 CONJUGATES OF POLYUNSATURATED FATTY ACIDS AND AMINE-CONTAINING COMPOUNDS AND USES THEREOF MEDWELL LAB LTD (IL) 2016-05-05 US disclosed
US-20160120995-A1 CONJUGATES OF POLYUNSATURATED FATTY ACIDS AND AMINE-CONTAINING COMPOUNDS AND USES THEREOF MEDWELL LAB LTD (IL) 2016-05-05 US disclosed
US-20160120995-A1 CONJUGATES OF POLYUNSATURATED FATTY ACIDS AND AMINE-CONTAINING COMPOUNDS AND USES THEREOF MEDWELL LAB LTD (IL) 2016-05-05 US disclosed
CN-102655839-A A cosmetic or dermatological composition with low stickiness, containing a lipophilic active ingredient OREAL 2012-09-05 CN disclosed
WO-2012093103-A2 TWO-PART COSMETIC PRODUCT L'OREAL (FR) 2012-07-12 WO disclosed
WO-2012032509-A2 CONJUGATES OF POLYUNSATURATED FATTY ACIDS AND AMINE-CONTAINING COMPOUNDS AND USES THEREOF MEDWELL LABORATORIES LTD. (IL) 2012-03-15 WO disclosed
WO-2012032509-A2 CONJUGATES OF POLYUNSATURATED FATTY ACIDS AND AMINE-CONTAINING COMPOUNDS AND USES THEREOF MEDWELL LABORATORIES LTD. (IL) 2012-03-15 WO disclosed
CN-101744739-A Use of an ester derived from 4-carboxy-2-pyrrolidinone as a solvent in cosmetic compositions and cosmetic compositions containing the ester OREAL 2010-06-23 CN disclosed
US-6368615-B1 POLYMER OF UNSATURATED ESTER OF SALICYLIC ACID GUTTAG ALVIN (US) 2002-04-09 US disclosed
US-6037338-A AND REDUCING RISK OF HEART ATTACKS GUTTAG ALVIN (US) 2000-03-14 US disclosed
US-5910511-A ALTERNATIVE TO ASPIRIN WHICH HAS LESSER UNDESIRABLE SIDE EFFECTS GUTTAG ALVIN (US) 1999-06-08 US disclosed
US-5760261-A ANTINFLAMMATORY AGENTS, ANTIPYRETICS, ANALGESICS; SIDE EFFECTREDUCTION GUTTAG ALVIN (US) 1998-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158070-A1 CONJUGATES OF POLYUNSATURATED FATTY ACIDS AND AMINE-CONTAINING COMPOUNDS AND USES THEREOF ALOX5, ALOX15B, ALOX15 KDM4E 3469/4885RECQL 3055/4885MEN1 4145/4885
US-20160120995-A1 CONJUGATES OF POLYUNSATURATED FATTY ACIDS AND AMINE-CONTAINING COMPOUNDS AND USES THEREOF ALOX5, ALOX15B, ALOX15 KDM4E 3431/4885RECQL 3054/4885MEN1 4304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.